Levetiracetam (Keppra) for Typical Absence Seizures
Levetiracetam is NOT FDA-approved for typical absence seizures and should generally be avoided as first-line therapy, as it demonstrates only modest efficacy (approximately 24% seizure freedom) and may paradoxically worsen absence seizures in some patients. 1, 2, 3
FDA-Approved Indications
The FDA label explicitly states that Keppra is approved ONLY for:
- Partial onset seizures (ages 4+)
- Myoclonic seizures in juvenile myoclonic epilepsy (ages 12+)
- Primary generalized tonic-clonic seizures (ages 6+)
Notably absent from this list: typical absence seizures 1
Evidence for Absence Seizures
Efficacy Data
The strongest clinical trial evidence comes from a 2011 multicenter randomized placebo-controlled trial that showed:
- Only 23.7% of patients achieved seizure freedom with levetiracetam (up to 30 mg/kg/day) versus 4.8% with placebo
- This difference just failed to reach statistical significance for the primary endpoint (p=0.08) 2
Real-world clinical practice data is even less encouraging:
- In a 2019 retrospective study of 72 children treated with levetiracetam for absence epilepsy, 74% discontinued the medication due to incomplete seizure control (59%) and/or intolerable side effects (41%) 4
- Only about one-quarter of children became seizure-free 4
Critical Pitfall: Seizure Aggravation
Levetiracetam can paradoxically worsen absence seizures in some patients. A 2011 case series documented 6 patients (childhood absence epilepsy, juvenile absence epilepsy, and epilepsy with myoclonic absences) who experienced aggravation of absences with a clear temporal relationship to levetiracetam introduction, which resolved upon dose reduction or withdrawal 3. This is a critical safety concern that must be monitored.
When Levetiracetam Might Be Considered
If levetiracetam is used off-label for absence seizures (after first-line agents like ethosuximide, valproate, or lamotrigine have failed or are contraindicated):
Dosing Approach
- Start low: When effective, levetiracetam controlled absence seizures at relatively low doses (mean 29 mg/kg/day) 4
- Lack of response at escalating doses (>40 mg/kg/day) should prompt early transition to alternative therapy rather than continued dose escalation 4
- Standard pediatric dosing would be: Start 20 mg/kg/day divided BID, increase by 20 mg/kg every 2 weeks up to 60 mg/kg/day 1
Monitoring Strategy
- Close clinical observation for seizure worsening, particularly in the first weeks after initiation
- If absences increase in frequency or duration, discontinue immediately 3
- If no improvement after reaching 30-40 mg/kg/day, consider switching rather than further escalation 4
Preferred Alternatives
For pharmaco-resistant absence seizures in childhood, the evidence suggests prioritizing ethosuximide, valproate, and lamotrigine in monotherapy or combination before considering levetiracetam 5. The cognitive side effects of antiepileptic drugs should be carefully weighed, as evidence that achieving complete seizure freedom improves cognitive outcomes in refractory absence epilepsy is weak 5.